Lasofoxifene (BioDeep_00000753049)

   


代谢物信息卡片


Lasofoxifene

化学式: C28H31NO2 (413.2354666)
中文名称: 拉索昔芬
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: C1CCN(C1)CCOC2=CC=C(C=C2)C3C(CCC4=C3C=CC(=C4)O)C5=CC=CC=C5
InChI: InChI=1S/C28H31NO2/c30-24-11-15-27-23(20-24)10-14-26(21-6-2-1-3-7-21)28(27)22-8-12-25(13-9-22)31-19-18-29-16-4-5-17-29/h1-3,6-9,11-13,15,20,26,28,30H,4-5,10,14,16-19H2/t26-,28+/m1/s1

描述信息

G - Genito urinary system and sex hormones > G03 - Sex hormones and modulators of the genital system > G03X - Other sex hormones and modulators of the genital system > G03XC - Selective estrogen receptor modulators
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator
C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen
C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen
C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist
C1892 - Chemopreventive Agent

同义名列表

1 个代谢物同义名

Lasofoxifene



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Hyemin Jeong, In Young Kim, Eun-Kyung Bae, Chan Hong Jeon, Kwang-Sung Ahn, Hoon-Suk Cha. Selective estrogen receptor modulator lasofoxifene suppresses spondyloarthritis manifestation and affects characteristics of gut microbiota in zymosan-induced SKG mice. Scientific reports. 2021 06; 11(1):11923. doi: 10.1038/s41598-021-91320-1. [PMID: 34099783]
  • Annica Andersson, Angelina I Bernardi, Alexandra Stubelius, Merja Nurkkala-Karlsson, Claes Ohlsson, Hans Carlsten, Ulrika Islander. Selective oestrogen receptor modulators lasofoxifene and bazedoxifene inhibit joint inflammation and osteoporosis in ovariectomised mice with collagen-induced arthritis. Rheumatology (Oxford, England). 2016 Mar; 55(3):553-63. doi: 10.1093/rheumatology/kev355. [PMID: 26424839]
  • Richard Eastell, David M Reid, Slobodan Vukicevic, Kristine E Ensrud, Andrea Z LaCroix, John R Thompson, David D Thompson, Steven R Cummings. Effects of 3 years of lasofoxifene treatment on bone turnover markers in women with postmenopausal osteoporosis. Bone. 2012 May; 50(5):1135-40. doi: 10.1016/j.bone.2012.02.004. [PMID: 22348983]
  • Syed M Meeran, Shweta N Patel, Yuanyuan Li, Samriddhi Shukla, Trygve O Tollefsbol. Bioactive dietary supplements reactivate ER expression in ER-negative breast cancer cells by active chromatin modifications. PloS one. 2012; 7(5):e37748. doi: 10.1371/journal.pone.0037748. [PMID: 22662208]
  • Lars Rejnmark, Leif Mosekilde. New and emerging antiresorptive treatments in osteoporosis. Current drug safety. 2011 Apr; 6(2):75-88. doi: 10.2174/157488611795684686. [PMID: 21524247]
  • Hisaya Kawate, Ryoichi Takayanagi. Efficacy and safety of bazedoxifene for postmenopausal osteoporosis. Clinical interventions in aging. 2011; 6(?):151-60. doi: 10.2147/cia.s15711. [PMID: 21753870]
  • Enrico M Messalli, Cono Scaffa. Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update. International journal of women's health. 2010 Aug; 1(?):11-20. doi: 10.2147/ijwh.s3894. [PMID: 21072271]
  • A Rogers, S J Glover, R Eastell. A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy. Bone. 2009 Dec; 45(6):1044-52. doi: 10.1016/j.bone.2009.07.089. [PMID: 19665601]
  • Bart L Clarke, Sundeep Khosla. New selective estrogen and androgen receptor modulators. Current opinion in rheumatology. 2009 Jul; 21(4):374-9. doi: 10.1097/bor.0b013e32832ca447. [PMID: 19412100]
  • Joseph P Salisbury, John C Williams. Docking study of triphenylphosphonium cations as estrogen receptor alpha modulators. Bioinformation. 2009; 3(7):303-7. doi: 10.6026/97320630003303. [PMID: 19293997]
  • Luigi Gennari, Daniela Merlotti, Vincenzo De Paola, Giuseppe Martini, Ranuccio Nuti. Bazedoxifene for the prevention of postmenopausal osteoporosis. Therapeutics and clinical risk management. 2008 Dec; 4(6):1229-42. doi: 10.2147/tcrm.s3476. [PMID: 19337430]
  • C Punyadeera, R Kamps, S Defrère, F Dijcks, A de Goeij, A Ederveen, G Dunselman, P Groothuis. Effects of selective oestrogen receptor modulators on proliferation in tissue cultures of pre- and postmenopausal human endometrium. The Journal of steroid biochemistry and molecular biology. 2008 Nov; 112(1-3):102-9. doi: 10.1016/j.jsbmb.2008.09.002. [PMID: 18832036]
  • Chandra Prakash, Kim A Johnson, Clinton M Schroeder, Michael J Potchoiba. Metabolism, distribution, and excretion of a next generation selective estrogen receptor modulator, lasofoxifene, in rats and monkeys. Drug metabolism and disposition: the biological fate of chemicals. 2008 Sep; 36(9):1753-69. doi: 10.1124/dmd.108.021808. [PMID: 18515329]
  • Chandra Prakash, Kim A Johnson, Mark J Gardner. Disposition of lasofoxifene, a next-generation selective estrogen receptor modulator, in healthy male subjects. Drug metabolism and disposition: the biological fate of chemicals. 2008 Jul; 36(7):1218-26. doi: 10.1124/dmd.108.020404. [PMID: 18372400]
  • Luigi Gennari, Daniela Merlotti, Fabrizio Valleggi, Giuseppe Martini, Ranuccio Nuti. Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development. Drugs & aging. 2007; 24(5):361-79. doi: 10.2165/00002512-200724050-00002. [PMID: 17503894]
  • Luigi Gennari. Lasofoxifene: a new type of selective estrogen receptor modulator for the treatment of osteoporosis. Drugs of today (Barcelona, Spain : 1998). 2006 Jun; 42(6):355-67. doi: 10.1358/dot.2006.42.6.973583. [PMID: 16845439]
  • Daniele Ouellet, Candace Bramson, Santos Carvajal-Gonzalez, Doina Roman, Edward Randinitis, Ann Remmers, Mark J Gardner. Effects of lasofoxifene on the pharmacokinetics and pharmacodynamics of single-dose warfarin. British journal of clinical pharmacology. 2006 Jun; 61(6):741-5. doi: 10.1111/j.1365-2125.2006.02589.x. [PMID: 16722839]
  • Eric A Ariazi, Jennifer L Ariazi, Fernando Cordera, V Craig Jordan. Estrogen receptors as therapeutic targets in breast cancer. Current topics in medicinal chemistry. 2006; 6(3):181-202. doi: . [PMID: 16515478]
  • Mark Gardner, Ann Taylor, Greg Wei, Albert Calcagni, Barbara Duncan, Ashley Milton. Clinical pharmacology of multiple doses of lasofoxifene in postmenopausal women. Journal of clinical pharmacology. 2006 Jan; 46(1):52-8. doi: 10.1177/0091270005283280. [PMID: 16397284]
  • Candace Bramson, Daniele Ouellet, Doina Roman, Edward Randinitis, Mark J Gardner. A single-dose pharmacokinetic study of lasofoxifene in healthy volunteers and subjects with mild and moderate hepatic impairment. Journal of clinical pharmacology. 2006 Jan; 46(1):29-36. doi: 10.1177/0091270005283278. [PMID: 16397281]
  • Osamu Chaki. [Next generation selective estrogen receptor modulators]. Clinical calcium. 2006 Jan; 16(1):145-52. doi: clica0601145152. [PMID: 16397365]
  • Robert A Moller, Jeannine M Fisher, Ann E Taylor, Sheela Kolluri, Mark J Gardner, R Scott Obach, Robert L Walsky. Effects of steady-state lasofoxifene on CYP2D6- and CYP2E1-mediated metabolism. The Annals of pharmacotherapy. 2006 Jan; 40(1):32-7. doi: 10.1345/aph.1g347. [PMID: 16368922]
  • Doina Roman, Candace Bramson, Daniele Ouellet, Edward Randinitis, Mark Gardner. Effect of lasofoxifene on the pharmacokinetics of digoxin in healthy postmenopausal women. Journal of clinical pharmacology. 2005 Dec; 45(12):1407-12. doi: 10.1177/0091270005282627. [PMID: 16291716]
  • Reina Armamento-Villareal, Sharmin Sheikh, Abroo Nawaz, Nicola Napoli, Cheryl Mueller, Linda R Halstead, Michael D Brodt, Matthew J Silva, Elisabetta Galbiati, Paola Lorenza Caruso, Maurizio Civelli, Roberto Civitelli. A new selective estrogen receptor modulator, CHF 4227.01, preserves bone mass and microarchitecture in ovariectomized rats. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2005 Dec; 20(12):2178-88. doi: 10.1359/jbmr.050801. [PMID: 16294271]
  • ". Lasofoxifene: CP 336156, CP-336156. Drugs in R&D. 2005; 6(1):56-60. doi: 10.2165/00126839-200506010-00008. [PMID: 15801869]
  • Tomoko Maeda, Hua Zhu Ke, Hollis Simmons, David Thompson. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies]. Clinical calcium. 2004 Oct; 14(10):85-93. doi: clica041015551563. [PMID: 15577137]
  • T R S Ozolins, U Gupta. Embryo/fetal toxicity assessment of lasofoxifene, a selective estrogen receptor modulator (SERM), in rats and rabbits. Birth defects research. Part B, Developmental and reproductive toxicology. 2004 Jun; 71(3):161-70. doi: 10.1002/bdrb.20010. [PMID: 15282737]
  • Walter P Weisenburger, Alan R Hagler, Melissa S Tassinari. Pre- and postnatal development studies of lasofoxifene, a selective estrogen receptor modulator (SERM), in Sprague-Dawley rats. Birth defects research. Part B, Developmental and reproductive toxicology. 2004 Jun; 71(3):171-84. doi: 10.1002/bdrb.20013. [PMID: 15282738]
  • Hua Zhu Ke, George L Foley, Hollis A Simmons, Victor Shen, David D Thompson. Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats. Endocrinology. 2004 Apr; 145(4):1996-2005. doi: 10.1210/en.2003-1481. [PMID: 14726439]
  • Karla C Morello, Gregory T Wurz, Michael W DeGregorio. SERMs: current status and future trends. Critical reviews in oncology/hematology. 2002 Jul; 43(1):63-76. doi: 10.1016/s1040-8428(02)00022-7. [PMID: 12098608]
  • H Z Ke, H Qi, K L Chidsey-Frink, D T Crawford, D D Thompson. Lasofoxifene (CP-336,156) protects against the age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2001 Apr; 16(4):765-73. doi: 10.1359/jbmr.2001.16.4.765. [PMID: 11316005]
  • H Z Ke, H Qi, D T Crawford, K L Chidsey-Frink, H A Simmons, D D Thompson. Lasofoxifene (CP-336,156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat. Endocrinology. 2000 Apr; 141(4):1338-44. doi: 10.1210/endo.141.4.7408. [PMID: 10746637]
  • H Z Ke, V M Paralkar, W A Grasser, D T Crawford, H Qi, H A Simmons, C M Pirie, K L Chidsey-Frink, T A Owen, S L Smock, H K Chen, W S Jee, K O Cameron, R L Rosati, T A Brown, P Dasilva-Jardine, D D Thompson. Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models. Endocrinology. 1998 Apr; 139(4):2068-76. doi: 10.1210/endo.139.4.5902. [PMID: 9528995]
  • I M Nilsson, S E Bergentz, U Hedner, K Kullenberg. Gastric fibrinolysis. Thrombosis et diathesis haemorrhagica. 1975 Nov; 34(2):409-18. doi: 10.1055/s-0038-1651400. [PMID: 807]